An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology - 07/05/21
Abstract |
Immune-mediated diseases and immunotherapeutics can negatively affect normal immune functioning and, consequently, vaccine safety and response. The COVID-19 pandemic has incited research aimed at developing a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. As SARS-CoV-2 vaccines are developed and made available, the assessment of anticipated safety and efficacy in patients with immune-mediated dermatologic diseases and requiring immunosuppressive and/or immunomodulatory therapy is particularly important. A review of the literature was conducted by a multidisciplinary committee to provide guidance on the safety and efficacy of SARS-CoV-2 vaccination for dermatologists and other clinicians when prescribing immunotherapeutics. The vaccine platforms being used to develop SARS-CoV-2 vaccines are expected to be safe and potentially effective for dermatology patients on immunotherapeutics. Current guidelines for the vaccination of an immunocompromised host remain appropriate when considering future administration of SARS-CoV-2 vaccines.
Le texte complet de cet article est disponible en PDF.Key words : COVID-19, immunomodulatory therapy, immunosuppressive therapy, SARS-CoV-2, vaccine
Abbreviations used : IL, mRNA, SARS-CoV-2, TNF, VAERD
Plan
Funding sources: None. |
|
IRB approval status: Not applicable. |
Vol 84 - N° 6
P. 1652-1666 - juin 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.